ID   EXT1_HUMAN              Reviewed;         746 AA.
AC   Q16394; B2R7V2; Q9BVI9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-MAR-2002, sequence version 2.
DT   10-MAY-2017, entry version 176.
DE   RecName: Full=Exostosin-1;
DE            EC=2.4.1.224;
DE            EC=2.4.1.225;
DE   AltName: Full=Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase;
DE   AltName: Full=Multiple exostoses protein 1;
DE   AltName: Full=Putative tumor suppressor protein EXT1;
GN   Name=EXT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=7550340; DOI=10.1038/ng1095-137;
RA   Ahn J., Luedecke H.-J., Lindow S., Horton W.A., Lee B., Wagner M.J.,
RA   Horsthemke B., Wells D.E.;
RT   "Cloning of the putative tumour suppressor gene for hereditary
RT   multiple exostoses (EXT1).";
RL   Nat. Genet. 11:137-143(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-320.
RC   TISSUE=Lung;
RX   PubMed=9119404; DOI=10.1006/geno.1996.4577;
RA   Luedecke H.-J., Ahn J., Lin X., Hill A., Wagner M.J., Schomburg L.,
RA   Horsthemke B., Wells D.E.;
RT   "Genomic organization and promoter structure of the human EXT1 gene.";
RL   Genomics 40:351-354(1997).
RN   [6]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=10679296; DOI=10.1006/bbrc.2000.2219;
RA   Kobayashi S., Morimoto K., Shimizu T., Takahashi M., Kurosawa H.,
RA   Shirasawa T.;
RT   "Association of EXT1 and EXT2, hereditary multiple exostoses gene
RT   products, in Golgi apparatus.";
RL   Biochem. Biophys. Res. Commun. 268:860-867(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=11518722; DOI=10.1172/JCI13737;
RA   Duncan G., McCormick C., Tufaro F.;
RT   "The link between heparan sulfate and hereditary bone disease: finding
RT   a function for the EXT family of putative tumor suppressor proteins.";
RL   J. Clin. Invest. 108:511-516(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=22660413; DOI=10.1038/ncb2502;
RA   Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G.,
RA   Geeraerts A., Ivarsson Y., Depoortere F., Coomans C., Vermeiren E.,
RA   Zimmermann P., David G.;
RT   "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.";
RL   Nat. Cell Biol. 14:677-685(2012).
RN   [9]
RP   REVIEW ON VARIANTS.
RX   PubMed=10679937;
RX   DOI=10.1002/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K;
RA   Wuyts W., Van Hul W.;
RT   "Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2
RT   genes.";
RL   Hum. Mutat. 15:220-227(2000).
RN   [10]
RP   VARIANTS EXT1 GLY-280 AND HIS-340.
RA   Raskind W.H., Matsushita M., Conrad E.U. III, Wells D.E.,
RA   Sandell L.J., Wagner M.J., Houck J.;
RT   "Spectrum of EXT1 mutations in hereditary multiple exostoses.";
RL   Am. J. Hum. Genet. 59:A280-A280(1996).
RN   [11]
RP   VARIANT EXT1 LEU-340.
RX   PubMed=8981950;
RA   Hecht J.T., Hogue D.A., Wang Y., Blanton S.H., Wagner M.J.,
RA   Strong L.C., Raskind W.H., Hansen M.F., Wells D.E.;
RT   "Hereditary multiple exostoses (EXT): mutational studies of familial
RT   EXT1 cases and EXT-associated malignancies.";
RL   Am. J. Hum. Genet. 60:80-86(1997).
RN   [12]
RP   VARIANTS EXT1 ASP-339 AND CYS-340.
RX   PubMed=9326317; DOI=10.1086/515505;
RA   Philippe C., Porter D.E., Emerton M.E., Wells D.E., Simpson A.H.R.W.,
RA   Monaco A.P.;
RT   "Mutation screening of the EXT1 and EXT2 genes in patients with
RT   hereditary multiple exostoses.";
RL   Am. J. Hum. Genet. 61:520-528(1997).
RN   [13]
RP   VARIANTS EXT1 GLY-280 AND SER-340.
RX   PubMed=9463333; DOI=10.1086/301726;
RA   Wuyts W., van Hul W., de Boulle K., Hendrickx J., Bakker E.,
RA   Vanhoenacker F., Mollica F., Luedecke H.-J., Sayli B.S.,
RA   Pazzaglia U.E., Mortier G., Hamel B.C.J., Conrad E.U. III,
RA   Matsushita M., Raskind W.H., Willems P.J.;
RT   "Mutations in the EXT1 and EXT2 genes in hereditary multiple
RT   exostoses.";
RL   Am. J. Hum. Genet. 62:346-354(1998).
RN   [14]
RP   VARIANTS EXT1 GLY-280; SER-280; HIS-340 AND HIS-627 DEL.
RX   PubMed=9521425;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:3<231::AID-HUMU8>3.0.CO;2-K;
RA   Raskind W.H., Conrad E.U. III, Matsushita M., Wijsman E.M.,
RA   Wells D.E., Chapman N., Sandell L.J., Wagner M.J., Houck J.;
RT   "Evaluation of locus heterogeneity and EXT1 mutations in 34 families
RT   with hereditary multiple exostoses.";
RL   Hum. Mutat. 11:231-239(1998).
RN   [15]
RP   VARIANTS EXT1 HIS-164; 235-PRO--LYS-239 DEL AND SER-316.
RX   PubMed=10441575; DOI=10.1086/302532;
RA   Bovee J.V.M.G., Cleton-Jansen A.-M., Wuyts W., Caethoven G.,
RA   Taminiau A.H.M., Bakker E., van Hul W., Cornelisse C.J.,
RA   Hogendoorn P.C.W.;
RT   "EXT-mutation analysis and loss of heterozygosity in sporadic and
RT   hereditary osteochondromas and secondary chondrosarcomas.";
RL   Am. J. Hum. Genet. 65:689-698(1999).
RN   [16]
RP   VARIANTS EXT1 VAL-486 AND LEU-496.
RX   PubMed=10480354; DOI=10.1007/s004399900058;
RA   Xu L., Xia J., Jiang H., Zhou J., Li H., Wang D., Pan Q., Long Z.,
RA   Fan C., Deng H.-X.;
RT   "Mutation analysis of hereditary multiple exostoses in the Chinese.";
RL   Hum. Genet. 105:45-50(1999).
RN   [17]
RP   VARIANT EXT1 215-MET--SER-221 DEL, AND VARIANT OSTEOCHONDROMA
RP   215-MET--SER-222 DELINS ILE.
RX   PubMed=11169766;
RX   DOI=10.1002/1097-0169(200102)48:2<149::AID-CM1005>3.0.CO;2-3;
RA   Bernard M.A., Hall C.E., Hogue D.A., Cole W.G., Scott A., Snuggs M.B.,
RA   Clines G.A., Luedecke H.-J., Lovett M., Van Winkle W.B., Hecht J.T.;
RT   "Diminished levels of the putative tumor suppressor proteins EXT1 and
RT   EXT2 in exostosis chondrocytes.";
RL   Cell Motil. Cytoskeleton 48:149-162(2001).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLN-27; ASP-164;
RP   ASN-316; ALA-486 AND PRO-496.
RX   PubMed=11391482; DOI=10.1086/321278;
RA   Cheung P.K., McCormick C., Crawford B.E., Esko J.D., Tufaro F.,
RA   Duncan G.;
RT   "Etiological point mutations in the hereditary multiple exostoses gene
RT   EXT1: a functional analysis of heparan sulfate polymerase activity.";
RL   Am. J. Hum. Genet. 69:55-66(2001).
CC   -!- FUNCTION: Glycosyltransferase required for the biosynthesis of
CC       heparan-sulfate. The EXT1/EXT2 complex possesses substantially
CC       higher glycosyltransferase activity than EXT1 or EXT2 alone.
CC       Appears to be a tumor suppressor. Required for the exosomal
CC       release of SDCBP, CD63 and syndecan (PubMed:22660413).
CC       {ECO:0000269|PubMed:11518722, ECO:0000269|PubMed:22660413}.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-D-glucosamine + beta-D-
CC       glucuronosyl-(1->4)-N-acetyl-alpha-D-glucosaminyl-proteoglycan =
CC       UDP + N-acetyl-alpha-D-glucosaminyl-(1->4)-beta-D-glucuronosyl-
CC       (1->4)-N-acetyl-alpha-D-glucosaminyl-proteoglycan.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-glucuronate + N-acetyl-alpha-D-
CC       glucosaminyl-(1->4)-beta-D-glucuronosyl-proteoglycan = UDP + beta-
CC       D-glucuronosyl-(1->4)-N-acetyl-alpha-D-glucosaminyl-(1->4)-beta-D-
CC       glucuronosyl-proteoglycan.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:Q9ES89};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- SUBUNIT: Forms a homo/hetero-oligomeric complex with EXT2.
CC       {ECO:0000269|PubMed:10679296}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10679296}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:10679296}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:10679296}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:10679296}. Note=The EXT1/EXT2 complex
CC       is localized in the Golgi apparatus.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DISEASE: Hereditary multiple exostoses 1 (EXT1) [MIM:133700]: EXT
CC       is a genetically heterogeneous bone disorder caused by genes
CC       segregating on human chromosomes 8, 11, and 19 and designated
CC       EXT1, EXT2 and EXT3 respectively. EXT is a dominantly inherited
CC       skeletal disorder primarily affecting endochondral bone during
CC       growth. The disease is characterized by formation of numerous
CC       cartilage-capped, benign bone tumors (osteocartilaginous exostoses
CC       or osteochondromas) that are often accompanied by skeletal
CC       deformities and short stature. In a small percentage of cases
CC       exostoses have exhibited malignant transformation resulting in an
CC       osteosarcoma or chondrosarcoma. Osteochondromas development can
CC       also occur as a sporadic event. {ECO:0000269|PubMed:10441575,
CC       ECO:0000269|PubMed:10480354, ECO:0000269|PubMed:11169766,
CC       ECO:0000269|PubMed:8981950, ECO:0000269|PubMed:9326317,
CC       ECO:0000269|PubMed:9463333, ECO:0000269|PubMed:9521425,
CC       ECO:0000269|Ref.10}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Tricho-rhino-phalangeal syndrome 2 (TRPS2) [MIM:150230]:
CC       A syndrome that combines the clinical features of tricho-rhino-
CC       phalangeal syndrome type 1 and multiple exostoses type 1. Affected
CC       individuals manifest multiple dysmorphic facial features including
CC       large, laterally protruding ears, a bulbous nose, an elongated
CC       upper lip, as well as sparse scalp hair, winged scapulae, multiple
CC       cartilaginous exostoses, redundant skin, and mental retardation.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. A chromosomal aberration resulting in the loss of
CC       functional copies of TRPS1 and EXT1 has been found in TRPS2
CC       patients.
CC   -!- DISEASE: Chondrosarcoma (CHDSA) [MIM:215300]: A malignant neoplasm
CC       derived from cartilage cells. Chondrosarcomas range from slow-
CC       growing non-metastasizing lesions to highly aggressive
CC       metastasizing sarcomas. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 47 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EXT1ID212.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S79639; AAB62283.1; -; mRNA.
DR   EMBL; AK313129; BAG35949.1; -; mRNA.
DR   EMBL; CH471060; EAW91972.1; -; Genomic_DNA.
DR   EMBL; BC001174; AAH01174.1; -; mRNA.
DR   EMBL; U70539; AAC51154.1; -; Genomic_DNA.
DR   CCDS; CCDS6324.1; -.
DR   RefSeq; NP_000118.2; NM_000127.2.
DR   UniGene; Hs.492618; -.
DR   ProteinModelPortal; Q16394; -.
DR   SMR; Q16394; -.
DR   BioGrid; 108432; 23.
DR   IntAct; Q16394; 2.
DR   MINT; MINT-120274; -.
DR   STRING; 9606.ENSP00000367446; -.
DR   CAZy; GT47; Glycosyltransferase Family 47.
DR   CAZy; GT64; Glycosyltransferase Family 64.
DR   iPTMnet; Q16394; -.
DR   PhosphoSitePlus; Q16394; -.
DR   BioMuta; EXT1; -.
DR   DMDM; 20141422; -.
DR   EPD; Q16394; -.
DR   MaxQB; Q16394; -.
DR   PaxDb; Q16394; -.
DR   PeptideAtlas; Q16394; -.
DR   PRIDE; Q16394; -.
DR   DNASU; 2131; -.
DR   Ensembl; ENST00000378204; ENSP00000367446; ENSG00000182197.
DR   GeneID; 2131; -.
DR   KEGG; hsa:2131; -.
DR   UCSC; uc003yok.3; human.
DR   CTD; 2131; -.
DR   DisGeNET; 2131; -.
DR   GeneCards; EXT1; -.
DR   GeneReviews; EXT1; -.
DR   HGNC; HGNC:3512; EXT1.
DR   HPA; HPA044394; -.
DR   MalaCards; EXT1; -.
DR   MIM; 133700; phenotype.
DR   MIM; 150230; phenotype.
DR   MIM; 215300; phenotype.
DR   MIM; 608177; gene.
DR   neXtProt; NX_Q16394; -.
DR   OpenTargets; ENSG00000182197; -.
DR   Orphanet; 55880; Chondrosarcoma.
DR   Orphanet; 502; Langer-Giedion syndrome.
DR   Orphanet; 321; Multiple osteochondromas.
DR   PharmGKB; PA27924; -.
DR   eggNOG; KOG1021; Eukaryota.
DR   eggNOG; ENOG410XTFH; LUCA.
DR   GeneTree; ENSGT00550000074496; -.
DR   HOGENOM; HOG000266990; -.
DR   HOVERGEN; HBG003459; -.
DR   InParanoid; Q16394; -.
DR   KO; K02366; -.
DR   OMA; VTTCKHG; -.
DR   OrthoDB; EOG091G0BDR; -.
DR   PhylomeDB; Q16394; -.
DR   TreeFam; TF314231; -.
DR   BioCyc; MetaCyc:HS00012-MONOMER; -.
DR   BRENDA; 2.4.1.224; 2681.
DR   BRENDA; 2.4.1.225; 2681.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   SIGNOR; Q16394; -.
DR   UniPathway; UPA00378; -.
DR   ChiTaRS; EXT1; human.
DR   GeneWiki; EXT1; -.
DR   GenomeRNAi; 2131; -.
DR   PRO; PR:Q16394; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000182197; -.
DR   CleanEx; HS_EXT1; -.
DR   ExpressionAtlas; Q16394; baseline and differential.
DR   Genevisible; Q16394; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:ProtInc.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0000139; C:Golgi membrane; TAS:BHF-UCL.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0050508; F:glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0015020; F:glucuronosyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0042328; F:heparan sulfate N-acetylglucosaminyltransferase activity; NAS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050509; F:N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0016757; F:transferase activity, transferring glycosyl groups; IDA:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0033692; P:cellular polysaccharide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0072498; P:embryonic skeletal joint development; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0015014; P:heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0007498; P:mesoderm development; IEA:Ensembl.
DR   GO; GO:0021772; P:olfactory bulb development; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; IMP:BHF-UCL.
DR   GO; GO:0006486; P:protein glycosylation; IEA:UniProtKB-UniPathway.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR004263; Exostosin.
DR   InterPro; IPR027670; Exostosin-1.
DR   InterPro; IPR015338; EXT_C.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   PANTHER; PTHR11062:SF173; PTHR11062:SF173; 1.
DR   Pfam; PF03016; Exostosin; 1.
DR   Pfam; PF09258; Glyco_transf_64; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disease mutation; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Glycosyltransferase;
KW   Golgi apparatus; Hereditary multiple exostoses; Manganese; Membrane;
KW   Metal-binding; Reference proteome; Signal-anchor; Transferase;
KW   Transmembrane; Transmembrane helix; Tumor suppressor.
FT   CHAIN         1    746       Exostosin-1.
FT                                /FTId=PRO_0000149648.
FT   TOPO_DOM      1      7       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      8     28       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     29    746       Lumenal. {ECO:0000255}.
FT   REGION      544    549       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   REGION      565    567       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   REGION      650    654       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   REGION      688    701       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   ACT_SITE    654    654       {ECO:0000250|UniProtKB:Q9ES89}.
FT   METAL       567    567       Manganese; catalytic.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   BINDING     518    518       Substrate.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   BINDING     595    595       Substrate.
FT                                {ECO:0000250|UniProtKB:Q9ES89}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    652    704       {ECO:0000250|UniProtKB:Q9ES89}.
FT   VARIANT      27     27       Q -> K (in EXT1; no loss of activity).
FT                                /FTId=VAR_012815.
FT   VARIANT     164    164       D -> H (in EXT1; loss of activity).
FT                                {ECO:0000269|PubMed:10441575}.
FT                                /FTId=VAR_012816.
FT   VARIANT     215    222       MLAKASIS -> I (in isolated
FT                                osteochondroma; somatic mutation).
FT                                {ECO:0000269|PubMed:11169766}.
FT                                /FTId=VAR_012818.
FT   VARIANT     215    221       Missing (in EXT1).
FT                                /FTId=VAR_012817.
FT   VARIANT     235    239       Missing (in multiple osteochondromas).
FT                                {ECO:0000269|PubMed:10441575}.
FT                                /FTId=VAR_012819.
FT   VARIANT     280    280       R -> G (in EXT1; loss of activity).
FT                                {ECO:0000269|PubMed:9463333,
FT                                ECO:0000269|PubMed:9521425,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_002370.
FT   VARIANT     280    280       R -> S (in EXT1; loss of activity).
FT                                {ECO:0000269|PubMed:9521425}.
FT                                /FTId=VAR_002371.
FT   VARIANT     316    316       N -> S (in chondrosarcoma; no loss of
FT                                activity). {ECO:0000269|PubMed:10441575}.
FT                                /FTId=VAR_012820.
FT   VARIANT     339    339       G -> D (in EXT1; loss of activity;
FT                                dbSNP:rs119103288).
FT                                {ECO:0000269|PubMed:9326317}.
FT                                /FTId=VAR_002372.
FT   VARIANT     340    340       R -> C (in EXT1; loss of activity; still
FT                                able to form an oligomeric complex;
FT                                dbSNP:rs119103290).
FT                                {ECO:0000269|PubMed:9326317}.
FT                                /FTId=VAR_002373.
FT   VARIANT     340    340       R -> H (in EXT1; loss of activity;
FT                                dbSNP:rs119103287).
FT                                {ECO:0000269|PubMed:9521425,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_002374.
FT   VARIANT     340    340       R -> L (in EXT1; loss of activity;
FT                                dbSNP:rs119103287).
FT                                {ECO:0000269|PubMed:8981950}.
FT                                /FTId=VAR_002375.
FT   VARIANT     340    340       R -> S (in EXT1; loss of activity).
FT                                {ECO:0000269|PubMed:9463333}.
FT                                /FTId=VAR_002376.
FT   VARIANT     486    486       A -> V (in EXT1; no loss of activity;
FT                                dbSNP:rs188859975).
FT                                {ECO:0000269|PubMed:10480354}.
FT                                /FTId=VAR_012821.
FT   VARIANT     496    496       P -> L (in EXT1; no loss of activity).
FT                                {ECO:0000269|PubMed:10480354}.
FT                                /FTId=VAR_012822.
FT   VARIANT     627    627       Missing (in EXT1; loss of activity).
FT                                {ECO:0000269|PubMed:9521425}.
FT                                /FTId=VAR_002377.
FT   MUTAGEN      27     27       Q->A,P: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN      27     27       Missing: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     164    164       D->E: Abolishes heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     164    164       Missing: Abolishes heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     316    316       N->A: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     316    316       Missing: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     486    486       A->H: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     486    486       Missing: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     496    496       P->H: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   MUTAGEN     496    496       Missing: No effect on heparan-sulfate
FT                                biosynthesis.
FT                                {ECO:0000269|PubMed:11391482}.
FT   CONFLICT     60     61       DA -> EP (in Ref. 1 and 3).
FT                                {ECO:0000305}.
SQ   SEQUENCE   746 AA;  86255 MW;  842CD7E6C1312C1A CRC64;
     MQAKKRYFIL LSAGSCLALL FYFGGLQFRA SRSHSRREEH SGRNGLHHPS PDHFWPRFPD
     ALRPFVPWDQ LENEDSSVHI SPRQKRDANS SIYKGKKCRM ESCFDFTLCK KNGFKVYVYP
     QQKGEKIAES YQNILAAIEG SRFYTSDPSQ ACLFVLSLDT LDRDQLSPQY VHNLRSKVQS
     LHLWNNGRNH LIFNLYSGTW PDYTEDVGFD IGQAMLAKAS ISTENFRPNF DVSIPLFSKD
     HPRTGGERGF LKFNTIPPLR KYMLVFKGKR YLTGIGSDTR NALYHVHNGE DVVLLTTCKH
     GKDWQKHKDS RCDRDNTEYE KYDYREMLHN ATFCLVPRGR RLGSFRFLEA LQAACVPVML
     SNGWELPFSE VINWNQAAVI GDERLLLQIP STIRSIHQDK ILALRQQTQF LWEAYFSSVE
     KIVLTTLEII QDRIFKHISR NSLIWNKHPG GLFVLPQYSS YLGDFPYYYA NLGLKPPSKF
     TAVIHAVTPL VSQSQPVLKL LVAAAKSQYC AQIIVLWNCD KPLPAKHRWP ATAVPVVVIE
     GESKVMSSRF LPYDNIITDA VLSLDEDTVL STTEVDFAFT VWQSFPERIV GYPARSHFWD
     NSKERWGYTS KWTNDYSMVL TGAAIYHKYY HYLYSHYLPA SLKNMVDQLA NCEDILMNFL
     VSAVTKLPPI KVTQKKQYKE TMMGQTSRAS RWADPDHFAQ RQSCMNTFAS WFGYMPLIHS
     QMRLDPVLFK DQVSILRKKY RDIERL
//
